By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo

TheMediTary.Com

Medical Information, Documents, News - TheMediTary.Com

  • Home
  • News
  • Drugs
  • Drugs A-Z
  • Medical Answers
  • About Us
  • Contact
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo
Search Drugs
  • Drugs
    • Latest Drugs
    • Drugs A-Z
    • Medical Answers
  • News
    • FDA Alerts
    • Medical News
    • Health
    • Consumer Updates
    • Children's Health
  • More TheMediTary.Com
    • About Us
    • Contact
Follow US
Home > Medical Answers > What's the dosing schedule for Skyrizi?

What's the dosing schedule for Skyrizi?

Answers by TheMediTary.Com - Last updated: 13-Jul-2023

For treatment of plaque psoriasis and psoriatic arthritis in adults, you’ll receive your first two starter doses of Skyrizi four weeks apart, then you’ll have an injection every 12 weeks thereafter.

  • If you are being treated for psoriatic arthritis, your doctor may prescribe Skyrizi to be used alone or in combination with non-biologic disease-modifying antirheumatic drugs (DMARDs), such as methotrexate.
  • Once you start your Skyrizi maintenance injections, you’ll have only 4 doses per year.

For treatment of Crohn's disease in adults, the dosing schedule is three intravenous (given into a vein) starter doses given 4 weeks apart (at Week 0, 4 and 8), then a subcutaneous (under the skin) injection given at Week 12, followed by an injection every 8 weeks thereafter.

  • After completing the initial starter doses, you will receive Skyrizi as an injection under the skin (subcutaneous) using the prefilled cartridge with an on-body injector. You can administer this at home after training from your healthcare provider. The injection dose is delivered in 5 minutes and you will not see the needle.
  • You will receive only 6 doses per year after you receive your starter doses for Crohn's disease management.

Before use, you should receive training on how to inject the medicine. Be sure to read the instructions for use before you start using Skyrizi and each time you get a refill. There may be new information you need to know. If you do not have the instructions, ask your pharmacist for a copy. Use this medicine exactly as directed by your doctor.

Can I use Skyrizi at home?

You can inject subcutaneous (under the skin) Skyrizi with a prefilled syringe or a pen injector for treatment of plaque psoriasis and psoriatic arthritis. You will receive the subcutaneous injections either in your doctor’s office or at home after training by your healthcare provider.

For Crohn's disease, the initial starter intravenous doses are given in a healthcare facility. Then you will receive Skyrizi as an injection under the skin (subcutaneous) using the prefilled cartridge with an on-body injector. You can administer this dose at home after training from your healthcare provider.

What is the typical dose of Skyrizi?

The recommended starter and maintenance dose of Skyrizi (risankizumab) for both plaque psoriasis and psoriatic arthritis is 150 mg given as a subcutaneous (under the skin) injection. ​

The recommended starter doses of Skyrizi for treatment of Crohn's disease is 600 mg administered by intravenous infusion over at least one hour for the first three doses (Week 0, 4, and 8). Then, the recommended maintenance dosage is 360 mg given by subcutaneous (under the skin) injection at Week 12, and then every 8 weeks, thereafter.

If a dose is missed, administer the dose as soon as possible, then resume dosing at the regularly scheduled time. If you inject too much Skyrizi, call your doctor right away for instructions.

Only use the dose of Skyrizi that your doctor prescribes.

What diseases are Skyrizi used for?

Skyrizi is used to treat adults with moderate or severe plaque psoriasis, psoriatic arthritis, and Crohn's disease.

  • Plaque psoriasis is a chronic (long-term) autoimmune disease in which the cells of your skin are replaced at an unusually fast rate. This causes raised silvery plaques that can be flaky, red, and itchy. In autoimmune diseases the body's immune system starts to mistakenly attack healthy cells and tissues.
  • Psoriatic arthritis is an inflammatory disease of the skin and joints and impacts approximately 30% of patients with psoriasis.
  • Crohn's disease is an inflammatory bowel disease (IBD) that is characterized by ongoing inflammation (pain and swelling) of the gastrointestinal tract. Crohn's-related inflammation usually affects the intestines but it may occur anywhere from the mouth to the anus.

This is not all the information you need to know about Skyrizi (risankizumab-rzaa) for safe and effective use and does not take the place of talking to your doctor about your treatment. Review the full Skyrizi information here and discuss this information and any questions you have with your doctor or other health care provider.

Share this Article

Featured questions

  • Skyrizi vs Humira for plaque psoriasis - How do they compare?
  • Who makes Skyrizi and where is it made?
  • What is Skyrizi used for and how does it work?
  • Does Skyrizi cause cancer?
  • Can you drink alcohol while taking Skyrizi?
  • Is Skyrizi approved for treating psoriatic arthritis?
  • How is Skyrizi injection administered?
  • How long does it take for Skyrizi to work?
  • Can these drugs be used in Thalassemia patients?
  • How does Lupron (leuprolide) work for prostate cancer?
  • What is the consideration to use nifidepine over amlodipine?
  • Hypertrophic cardiomyopathy/mechanical heart valve?
Related Drugs
Fidanacogene Elaparvovec
Cerave Anti-Itch (Hydrocortisone topical)
Centrum Adult (Multivitamins and minerals)
Crovalimab
Cyltezo Prefilled Syringe (Adalimumab)
Zepbound Pen (Tirzepatide)
Mylanta One (Calcium carbonate, magnesium hydroxide, and simethicone)
Uretron Ds (Hyoscyamine, methenamine, methylene blue, phenyl salicylate, sodium biphosphate)
Medihoney Wound And Burn Dressing (Topical emollients)
Lidotrode
Libervant (Diazepam (buccal))
Moderna Covid-19 (Covid-19 (6m-11y) vaccine, moderna (2024-2025))
Beqvez (Fidanacogene elaparvovec)
Beqvez (Fidanacogene elaparvovec)
Beqvez (Fidanacogene elaparvovec)

Categories

  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health

About US

Welcome to TheMediTary.Com

Our website provides reliable and up-to-date information on various medical topics. We empower individuals to take charge of their health by simplifying complex medical jargon and providing practical tips and advice. We prioritize the privacy and confidentiality of our users and welcome feedback to improve our services.

Website use data of FDA and other sources

DMCA.com Protection Status Truste Protection Status Trust Mark Protection Status
HONcode logo We comply with the HONcode standard for trustworthy health information.
Quick Link
  • About Us
  • Contact Us
  • Editorial Policy
  • Privacy Policy
  • Accessibility Policy
  • Terms & Conditions
  • Disclaimer
  • DMCA
  • Do Not Sell My Personal Information
  • Sitemap
  • Care Notes
  • Health Guide
  • Professional
Drugs
  • New Drugs
  • Medical Answers
  • Drugs A-Z
  • Drug Classes
  • Drug Dosage
  • Pill Identifier
  • Consumer Infor
  • Side Effects
  • Inactive Ingredients
  • Pregnancy Warnings
  • Patient Tips
  • Treatments
News
  • Latest News
  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health
Find US
  • Medium
  • Google Site
  • Blogspot
  • API
  • Reddit
  • Tumblr
  • Scoop.it
  • Substack
  • Wordpress
  • Wix
  • Behance

© 2025 TheMediTary.Com All rights reserved. Operated by